The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
2000
Cost-Effectiveness of High Dose Chemotherapy for Lymphoma
publication
Evidence: moderate
Author Information
Author(s): Beard S M, Lorigan P C, Sampson F C
Primary Institution: ScHARR, University of Sheffield
Hypothesis
Is high dose chemotherapy cost-effective for treating relapsed Hodgkin's disease and non-Hodgkin's lymphoma?
Conclusion
High dose chemotherapy is both life-saving and cost-effective for patients with relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
Supporting Evidence
- High dose chemotherapy provides an additional patient benefit of 0.8–1.1 life years over standard chemotherapy.
- The estimated incremental cost per life year gained is £12,800–£17,600.
Takeaway
This study found that using high dose chemotherapy can help people live longer and is worth the money spent on it.
Methodology
The study analyzed key trials and case series to evaluate the cost-effectiveness of high dose chemotherapy.
Statistical Information
Confidence Interval
0.8–1.1 life years
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website